COST-EFFECTIVENESS OF SECOND-LINE NILOTINIB VERSUS DASATINIB FOR THE TREATMENT OF PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOID LEUKEMIA-CHRONIC PHASE (PH plus CML-CP) IN ITALY

被引：0
|
作者：
Maheshwari, V [1 ]
Tran, D. [2 ]
Agostoni, G. [3 ]
Filioussi, K. [3 ]
Viana, R. [4 ]
机构：
[1] Novartis Healthcare Pvt Ltd, Hyderabad, Andhra Pradesh, India
[2] Cornerstone Res Grp Inc, Burlington, ON, Canada
[3] Novartis Farma SpA, Origgio, Italy
[4] Novartis, East Hannover, NJ USA
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN176
引用
收藏
页码：S470 / S470
页数：1
相关论文
共 50 条
  • [21] Use Of Nilotinib As a First Line Treatment In Adult Patients With Philadelphia Chromosome-Positive and Chronic Phase Myeloid Leukemia
    Saydam, Guray
    Haznedaroglu, Ibrahim C.
    Kaynar, Leylagul
    Yavuz, Akif S.
    Ali, Ridvan
    Guvenc, Birol
    Akay, Olga M.
    Baslar, Zafer
    Ozbek, Ugur
    Sonmez, Mehmet
    Aydin, Demet
    Pehlivan, Mustafa
    Undar, Bulent
    Dagdas, Simten
    Ayyildiz, Orhan M.
    Akkaynak, Diyar Z.
    Dag, Ilkiz M.
    Ilhan, Osman
    BLOOD, 2013, 122 (21)
  • [22] Adherence to treatment with second-line therapies, dasatinib and nilotinib, in patients (pts) with chronic myeloid leukemia (CML).
    Yood, M. Ulcickas
    Oliveria, S. A.
    Hirji, I.
    Phillips, S.
    Cziraky, M. J.
    Davis, C. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [23] Treatment Free Remission (TFR) in Chronic Myeloid Leukemia-Chronic Phase (CML-CP), Kuwait Experience
    Alhuraiji, Ahmad
    Hasaneen, Mahmoud
    Hassanein, Mona
    Ram, Mohan
    Khadadah, Fatima
    Kunhikrishnan, Anita
    Shah, Abdul Rashid
    Hamadah, Abdulaziz
    Alshemmari, Salem
    Pandita, Ramesh
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S297 - S297
  • [24] Imatinib mesylate (STI571) therapy of Philadelphia chromosome-positive chronic myeloid leukemia in early chronic phase (Ph plus CML early CP).
    Kantarjian, HM
    Cortes, J
    O'Brien, S
    Giles, F
    Thomas, D
    Garcia-Manero, G
    Faderl, S
    Rios, MB
    Shan, J
    Hayes, K
    Keating, MJ
    Freireich, EJ
    Talpaz, M
    BLOOD, 2001, 98 (11) : 137A - 137A
  • [25] COST-EFFECTIVENESS ANALYSIS OF NILOTINIB VERSES IMATINIB FOR THE TREATMENT OF CHRONIC PHASE PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKAEMIA
    Mildred, M.
    Ward, S.
    Squires, H.
    Gray, E.
    HAEMATOLOGICA, 2012, 97 : 314 - 314
  • [26] A phase II study of dasatinib therapy in children and adolescents with newly diagnosed chronic phase chronic myelogenous leukemia (CML-CP) or Philadelphia chromosome-positive (Ph plus ) leukemias resistant or intolerant to imatinib.
    Zwaan, Michel
    Stork, Linda C.
    Bertrand, Yves
    Gore, Lia
    Hijiya, Nobuko
    De Souza, Carmino
    Lee, Maria Lucia de Martino
    Bradley-Garelik, M. Brigid
    Kearns, Pamela
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [27] Justification for Asciminib Dosing in Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia (Ph plus CML-CP) with and without the T315I Mutation
    Combes, Francois Pierre
    Li, Ying Fei
    Sy, Sherwin K. B.
    Lorenzo, Sebastien
    Dasgupta, Kohinoor
    Kapoor, Shruti
    Hoch, Matthias
    Ho, Yu-Yun
    BLOOD, 2022, 140 : 6791 - 6792
  • [28] Dasatinib plus SMO antagonist versus dasatinib alone for treating patients (pts) with newly diagnosed Philadelphia chromosome-positive (Ph plus ) chronic myeloid leukemia in chronic phase (CML-CP): Design of CA180-363, a phase II, open-label randomized trial
    Trudel, Geralyn C.
    Paliwal, Prashni
    Lainas, Ioannis
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [29] Estimating Long-Term Life Expectancy in Philadelphia Chromosome Positive (Ph plus ) Chronic Phase Chronic Myeloid Leukemia (CML-CP): Results of A Microsimulation Model
    Snedecor, Sonya J.
    Ji, Xiang
    Magestro, Matthew
    Stein, Andrew M.
    Botteman, Marc
    BLOOD, 2012, 120 (21)
  • [30] EFFICACY OF NILOTINIB IN PATIENTS (PTS) WITH NEWLY DIAGNOSED, PREVIOUSLY UNTREATED PHILADELPHIA CHROMOSOME (PH)-POSITIVE CHRONIC MYELOGENOUS LEUKEMIA IN EARLY CHRONIC PHASE (CML-CP)
    Cortes, J.
    Jones, D.
    O'Brien, S.
    Ferrajoli, A.
    Borhtakur, G.
    Burger, J.
    Wierda, W.
    Garcia-Manero, G.
    Letvak, L.
    Kantarjian, H.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 48 - 48
12345